Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $33.2400 (-4.24%) ($33.2400 - $34.8700) on Wed. Nov. 10, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.21% (three month average) | RSI | 59 | Latest Price | $33.2400(-4.24%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.2% a day on average for past five trading days. | Weekly Trend | TGTX advances 4.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(65%) IBB(62%) ARKK(61%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -1.605% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-19%) UNG(-7%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.605% (StdDev 3.21%) | Hourly BBV | -2.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $34.6(-3.93%) | 10 Day Moving Average | $33.48(-0.72%) | 20 Day Moving Average | $32.85(1.19%) | To recent high | -6.6% | To recent low | 53.3% | Market Cap | $4.21b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |